Internal Medicine, Endocrinology, Diabetes, & Metabolism · Lafayette, IN
NPI
1235198342
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2600 Ferry St
Lafayette, IN, 47904
Phone (765) 448-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$180K
6,233 services
Medicare patients, 2024
847
Average age 74
Drug cost, 2024
$2.6M
7,742 prescriptions
Company payments, 2025
$39.48
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shannon K Oates was code J0897 (injection, denosumab, 1 mg), 4,560 times for 47 patients. In total Shannon K Oates billed 6,233 services in 22 codes, and Medicare paid $180K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-02-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,560 | 47 | $20.27 | $92K |
| 99214 Office E&M - Established | Office | 758 | 464 | $84.98 | $64K |
| 95251 Test - Miscellaneous | Office | 335 | 183 | $24.63 | $8,252 |
| 77080 Standard X-ray | Office | 318 | 318 | $8.76 | $2,784 |
| 96372 Injection Administration | Office | 77 | 48 | $10.55 | $812 |
| 99213 Office E&M - Established | Office | 38 | 33 | $50.51 | $1,920 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 31 | 31 | $11.82 | $367 |
| 99215 Office E&M - Established | Office | 26 | 24 | $114.39 | $2,974 |
| 99205 Office E&M - New | Office | 25 | 25 | $138.77 | $3,469 |
| 90662 Vaccine Product | Office | 13 | 13 | $81.82 | $1,064 |
| G0008 Administration of influenza virus vaccine | Office | 13 | 13 | $30.10 | $391 |
| 83036 Blood Count | Office | 11 | 11 | $9.52 | $105 |
By year: 2022 $150K for 5,691 services; 2023 $137K for 4,749 services; 2024 $180K for 6,233 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 11 | 11 | $9.52 | $105 |
Medicare prescription drug claims, 2024
In 2024, the drug Shannon K Oates prescribed most often to Medicare patients was Levothyroxine Sodium, with 766 prescriptions and refills. In total Shannon K Oates wrote 7,742 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 766 | 2,135 | 206 | $7,669 |
| Mounjaro Tirzepatide | 455 | 562 | 71 | $589K |
| Metformin Hcl Er Metformin Hcl | 371 | 1,050 | 106 | $3,984 |
| Glimepiride Generic | 370 | 1,030 | 101 | $3,868 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 324 | 686 | 110 | $63K |
| Metformin Hcl Generic | 292 | 832 | 86 | $3,217 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 242 | 502 | 96 | $25K |
| Atorvastatin Calcium Generic | 208 | 586 | 56 | $1,811 |
| Ozempic Semaglutide | 206 | 268 | 40 | $246K |
| Trulicity Dulaglutide | 179 | 260 | 40 | $240K |
| Novolog Flexpen Insulin Aspart | 166 | 296 | 56 | $43K |
| Lisinopril Generic | 161 | 455 | 45 | $1,144 |
| Humalog Kwikpen U-100 Insulin Lispro | 160 | 296 | 50 | $57K |
| Jardiance Empagliflozin | 158 | 384 | 45 | $222K |
| Pioglitazone Hcl Generic | 135 | 394 | 41 | $2,088 |
Brand drugs: 3,405 claims; generic drugs: 3,683 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shannon K Oates $39.48 ($39.48 in general payments such as food, travel and fees) from 1 company. The largest payer was Medtronic, Inc. with $39.48.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 1 | $39.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.